Fluticasone  | | Systematic (IUPAC) name | S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)- 6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo- 6,7,8,11,12,14,15,16-octahydrocyclopenta[a] phenanthrene-17-carbothioate | | Identifiers | | CAS number | 90566-53-3 80474-14-2 (propionate) | | ATC code | D07AC17 & D07AC04 (topical) | | PubChem | 5311101 | | DrugBank | APRD00065 | | ChemSpider | 4470631 | | Chemical data | | Formula | C22H27F3O4S | | Mol. mass | 444.508 g/mol | | SMILES | eMolecules & PubChem | | Pharmacokinetic data | | Bioavailability | 0.51% (Intranasal) | | Protein binding | 91% | | Metabolism | Intranasal Hepatic (CYP3A4-mediated) | | Half life | 10 hours | | Excretion | Renal | | Therapeutic considerations | | Pregnancy cat. | C for Intranasal and Inhaled | | Legal status | POM(UK) ℞-only(US) | | Routes | Intranasal, Inhaled, Topical Cream or Ointment
| Fluticasone is a synthetic glucocorticoid. Both the furoate and propionate forms are used as topical anti-inflammatories: [edit] See also
Corticosteroids - glucocorticoid/receptor and mineralocorticoid/receptor (A07EA, C05AA, D07, D10AA, H02, R01AD, R03BA, S01BA, S02B, and S03B) (Endogenous in CAPS) | | Mineralocorticoids (3-one, 4-ene, no FG at 16) | | | Glucocorticoids (3-one, 4-ene, 11-FG, 17-hydroxy) | | | | Aldosterone antagonists | | | | Synthesis | | | | | | |